Arteriovenous fistulas are the standard of care in hemodialysis. Unfortunately, they have a 50 - 60% 1-year failure rate, resulting in catheter reliance, interventions, and many other complications that adversely impact patients.
At VenoStent, we are working to improve the usability and durability of AVFs for more reliable dialysis. This could have a positive impact on patient care and quality of life for chronic kidney disease (CKD) patients.
If you are eligible for this trial and elect to participate, you will be compensated for your participation. Ask your doctor for more details.
SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational device. Limited by federal law to investigational use.